First EU Medicine for Early Brain ALD in Boys Ages 2–12

Nezglyal is an oral suspension of leriglitazone (13.7 mg/mL), a selective PPAR-gamma agonist. On 21 September 2026, the European Commission granted a marketing authorisation under exceptional circumstances for Nezglyal across the EU (EMA product EMEA/H/C/006693; MA EU/1/26/2060/001). SmPC indication: treatment of cerebral adrenoleukodystrophy (cALD) in males with adrenoleukodystrophy (ALD) aged 2 to 12 years with non-gadolinium-enhancing (Gd-negative) brain lesions on MRI and a Neurological Functional Score (NFS) of 0 or 1. Marketing authorisation holder: Minoryx Therapeutics S.L., Mataró, Spain. Commercialisation in Europe is licensed to Neuraxpharm. Company materials describe first launch expected in Germany by end of 2026, with other member-state launches pending reimbursement — authorised is not funded.

Distinct path — not this label: Haematopoietic stem cell transplantation (HSCT) or gene therapy–based HSCT for more advanced / Gd-positive disease is not this approved oral suspension treatment pathway. Adult cALD programmes (for example CALYX NCT05819866) and Rett syndrome research (TREE) are not the EU paediatric Gd-negative SmPC population. FDA marketing authorisation for leriglitazone / Nezglyal is not confirmed on sources used here. Today’s approved EU pharmacological pathway for early Gd-negative paediatric cALD is Nezglyal EMEA/H/C/006693.

Where this is taking place

Approved prescription route today: European Union — EC-authorised Nezglyal for the SmPC population above; prescription only; start and monitor under a physician experienced in neurodegenerative disease. Suspected adverse reactions: follow national reporting systems (SmPC §4.8 / package leaflet); MAH pharmacovigilance contact listed on SmPC as pharmacovigilanceEU@minoryx.com / Minoryx Therapeutics S.L. Neuraxpharm is the European commercial partner (company announcement 25 Sep 2026). Member-state pharmacy availability and reimbursement vary — first commercial launch framed by the companies as Germany by end of 2026.

United States / Canada / other regulators: Nezglyal / leriglitazone marketing authorisation not confirmed on FDA, Health Canada, MHRA, TGA, PMDA/MHLW, or Swissmedic sources used for this article. Do not import on your own. An EU bottle is not a foreign Product Monograph.

Named research programme (evidence, not walk-in enrolment): NEXUS / MT-2-02 — open-label Phase 2/3 paediatric study; EudraCT 2019-000654-59; ClinicalTrials.gov NCT04528706 (registry status unknown when retrieved; SmPC uses study code MT-2-02). Sponsor: Minoryx Therapeutics, S.L. Adult Gd-positive programme CALYX — NCT05819866 (active but no longer taking new patients) is a separate population.

The practical route in the EU is an ALD / leukodystrophy / paediatric neurology centre confirming genetics, MRI Gd status, NFS, and whether labelled Nezglyal fits — and how HSCT timing interacts if lesions progress.

Approval matrix

Access by country

• European Union: Ask a clinician experienced in ALD / leukodystrophy whether labelled Nezglyal fits for a boy 2–12 with Gd-negative MRI lesions and NFS 0 or 1. Path: confirm ALD genetics and imaging → specialist initiation → once-daily oral suspension from SmPC height/weight tables → hepatic enzyme monitoring → national reimbursement rules. Germany is the company-framed first launch market by end of 2026. Other member states: confirm local launch and funding with the treating centre. No list price or copay dollars in this article.
• United States / Canada / UK / Australia / Japan / Switzerland / other countries: Authorisation not confirmed on sources used here. Ask the local specialist what legal special-access / named-patient options exist, whether referral to an EU centre is appropriate, or whether waiting for a home decision is the realistic option. Do not import on your own.

Who is eligible

This is an early paediatric cALD conversation — not a claim that Nezglyal replaces HSCT for every ALD stage, and not a US label.

European Union (SmPC 4.1 / 4.2 / 4.3):

• Indication: Cerebral adrenoleukodystrophy in males with ALD aged 2 to 12 years with non-Gd-enhancing (Gd-negative) brain lesions on MRI and NFS of 0 or 1.
• Form: 13.7 mg/mL oral suspension; 100 mL bottle with 12 mL oral syringe (0.5 mL graduations).
• Supervision: Initiate and monitor under a physician experienced in neurodegenerative disease.
• Contraindications: Hypersensitivity to leriglitazone or excipients; hypersensitivity to thiazolidinediones; cardiac failure or history of cardiac failure (NYHA I–IV).
• Not established: Children under 2 years; hepatic impairment (use not recommended); moderate–severe renal impairment (GFR <60 mL/min) not recommended.
• HSCT interaction: Discontinue Nezglyal at least five days before starting HSCT conditioning (SmPC).

Not labelled on the sources checked for this article:

• Adult cALD as the SmPC population.
• Gd-positive paediatric lesions as the authorised population (NEXUS enrolled both; the authorised indication is Gd-negative with NFS 0 or 1).
• FDA or Health Canada marketing authorisation.

What the pivotal study showed (NEXUS / MT-2-02)

Study MT-2-02 (NEXUS) — open-label, multicentre Phase 2/3 study in male paediatric patients aged 2–12 with cALD (SmPC §5.1; EudraCT 2019-000654-59; NCT04528706).

• Design: Open-label; no randomised comparator. All patients received leriglitazone plus standard care; HSCT allowed when clinically indicated. Efficacy assessed to week 96 or the visit prior to HSCT.
• Enrolled: n=23 (7 aged 2–5; 16 aged 6–12; mean age 7.7 years). Baseline populations: Gd-negative (population 1, n=9) and Gd-positive (population 2, n=14). Baseline NFS 0–1; MFD 0 for all.
• Evaluable set: n=20 (3 population-2 patients discontinued before week 24 and were excluded from the arrested-disease evaluable set).
• Primary endpoint: Proportion with clinically and radiologically arrested disease at week 96 or visit prior to HSCT, compared with an expected natural-history arrest rate of ~10%. Arrested disease required NFS change ≤5, absence of major functional disability, and no MRI lesion progression per pre-specified criteria.
• Overall evaluable: 7/20 (35%; 95% CI 15.4–100%) met arrested disease — primary endpoint met versus the 10% natural-history benchmark (SmPC).
• Gd-negative cohort (population 1, authorised-like): 6/9 (66.7%; 95% CI 29.9–100%) arrested disease. All 9 kept NFS change ≤5 and remained MFD-free; 6/9 remained GIS=0.
• The evidence is open-label, with a small number of patients and a historical natural-history benchmark. It is not a large randomised placebo-controlled pivotal of the kind used for many common diseases. Authorisation is under exceptional circumstances with post-authorisation obligations (PASS MT-4-01; registry effectiveness study; annual updates).

How it is taken

From the EU SmPC (name the source in clinic conversations):

• Once daily by mouth, preferably after breakfast at the same time each day.
• Dose from height- and weight-based tables (SmPC Table 1 ages 2–5; Table 2 ages 6–12) — volumes in mL of the 13.7 mg/mL suspension.
• Shake bottle ~30 seconds before each dose; measure with the supplied oral syringe; do not double a missed dose.
• Recheck growth every 6 months to adjust dose.
• Hepatic enzymes before start and regularly on treatment (quarterly first 6 months, then every 6 months). Suspend if ALT >3× ULN confirmed (SmPC Table 3).
• Stop ≥5 days before HSCT conditioning if transplant is planned.

Exact mL for a given child belong on the prescribing clinician’s calculation from the current SmPC — this article does not reprint every cell of the dose tables as a home calculator.

Safety (what the label puts first)

SmPC highlights that matter for caregivers first:

• Very common: oedema / fluid retention (including eyelid oedema) — 17.4% oedema in the paediatric SmPC narrative; oedema listed as very common in the tabulated list.
• Common in children (examples): weight increased (8.7%), eyelid oedema (8.7%), leukopenia (8.7%), neutropenia (8.7%); also anaemia, headache, night sweats, increased appetite, NT-proBNP increase.
• Contraindicated in cardiac failure / history of cardiac failure and thiazolidinedione hypersensitivity.
• Hepatic monitoring required; do not start if baseline AST/ALT >2× ULN or bilirubin >1.5× ULN (unless Gilbert’s).
• Do not use with blood-glucose-lowering medicines (hypoglycaemia risk); caution with strong/moderate CYP2C8 or CYP3A inhibitors/inducers.
• Sorbitol content — avoid in hereditary fructose intolerance.
• Class cautions: bladder symptoms prompt medical review; bone fracture / growth monitoring unknowns in long-term paediatrics.

Exceptional-circumstances authorisation means the company must keep submitting safety and long-term effectiveness data; the SmPC can change after annual re-assessment.

How to talk to a doctor

Bring this page to an ALD / leukodystrophy / paediatric neurology clinic and ask:

1. “Does my son’s MRI show Gd-negative lesions, and is his NFS 0 or 1 — does labelled EU Nezglyal fit?”
2. “How do we weigh Nezglyal against watching, HSCT, or referral timing if lesions become Gd-positive?”
3. “What does once-daily suspension dosing and liver-blood monitoring look like for his height and weight?”
4. “In our country, is Nezglyal launched and funded, or what legal access path exists?”
5. If outside the EU: “Has our regulator authorised leriglitazone, or should we discuss special access / referral rather than importing?”

Research and regulatory team

• MAH: Minoryx Therapeutics S.L., Av Ernest Lluch 32, TCM3, 08302 Mataró, Barcelona, Spain (SmPC).
• EU commercial partner: Neuraxpharm Group (company EC announcement 25 Sep 2026).
• Batch release manufacturer (SmPC Annex II): Delpharm Huningue S.A.S., Huningue, France.
• NEXUS sponsor: Minoryx Therapeutics, S.L. (NCT04528706 / EudraCT 2019-000654-59).
• NEXUS sites named on CT.gov (examples): CHU Kremlin Bicêtre (Paris); Universitätsmedizin Göttingen; UKE Hamburg; Hospital Sant Joan de Déu (Barcelona); site in Buenos Aires — historical trial geography, not a commercial pharmacy list.
• CHMP opinion: 23 July 2026; EC decision: 21 September 2026.

EU close-up: authorised under exceptional circumstances

EC MA is valid in EU member states plus Norway, Iceland, and Liechtenstein (company / EMA description). That is not automatic UK MHRA, Swissmedic, FDA, or Health Canada authorisation. “Exceptional circumstances” means complete data could not be obtained because of rarity — yearly EMA review of new information continues. Launch and reimbursement still run country by country; authorised is not funded.

Canada close-up: authorisation not confirmed

No Health Canada DIN / NOC for Nezglyal asserted on sources used here. Ask a Canadian leukodystrophy / genetics clinic what legal paths exist in Canada. Do not treat an EU bottle as a Canadian care plan.

Bottom line

Nezglyal is the first EC-authorised pharmacological treatment for early Gd-negative cALD in boys 2–12 with NFS 0 or 1, granted 21 September 2026 under exceptional circumstances. Access today is an EU specialist prescription conversation (Germany framed as first launch), supported by open-label NEXUS arrested-disease results — not a US pack, not a DIY import, and not a substitute for HSCT planning when disease stage requires it. Authorized is not funded.

Primary sources

1. EMA EPAR overview — Nezglyal (EC decision 21 Sep 2026; CHMP opinion 23 Jul 2026).
2. EMA Product Information / SmPC PDF — nezglyal-epar-product-information_en.pdf (first published 24 Sep 2026 on EMA page).
3. ClinicalTrials.gov — NCT04528706 (NEXUS / MIN-102).
4. EU Clinical Trials Register — EudraCT 2019-000654-59.
5. Company EC announcement (Neuraxpharm / Minoryx) — 25 Sep 2026 (launch sequencing; labeled as company).

---

Not medical advice. Authorized is not funded.